Advertisement

Pharmacogenetics in Potential Herb–Drug Interactions: Effects of Ginseng on CYP3A4 and CYP2C9 Allelic Variants

  • Alice Luu
  • Brian C. Foster
  • Kristina L. McIntyre
  • Teresa W. Tam
  • John T. Arnason
Chapter
Part of the Recent Advances in Phytochemistry book series (RAPT, volume 41)

Abstract

This chapter focuses on the role of ginseng in potential herb–drug interactions through inhibition of cytochrome P450 enzymes CYP3A4 and three polymorphisms of CYP2C9. Using commercial ginseng products and preparations made from authentic ginseng roots, CYP3A4 but not CYP2C9 inhibition correlated significantly with total ginsenoside content of the ginseng products tested. The inhibition of CYP2C9 was low for the three allelic forms and the profile of inhibition by product did not vary with the three polymorphisms tested. These in vitro results suggest that CYP3A4 inhibition, but not CYP2C9 inhibition, may warrant further study in a clinical setting.

Keywords

Drug Interaction Nicotinamide Adenine Dinucleotide Phosphate Ginseng Root CYP2C9 Gene Natural Health Product 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

Extraction and HPLC-DAD methods were kindly validated and provided by Paula Brown (NHP Research Group, British Columbia Institute of Technology, Burnaby, Canada). This project was funded by the Ontario Ginseng Innovation and Research Centre (OGIRC).

References

  1. 1.
    Sharma SK, Pandit MK (2009) A new species of Panax from Sikkim Himalaya, India. Syst Bot 34:434–438CrossRefGoogle Scholar
  2. 2.
    Bahrke MS, Morgan WP (1994) Evaluation of the ergogenic properties of ginseng. Sports Med 18:229–248PubMedCrossRefGoogle Scholar
  3. 3.
    Janetzki K, Morreale AP (1997) Probable interaction between warfarin and ginseng. Am J Health Syst Pharm 54:692–693Google Scholar
  4. 4.
    Shader RI, Greenblatt DJ (1985) Phenelzine and the dream machine – ramblings and reflections. J Clin Psychopharmacol 5:65PubMedCrossRefGoogle Scholar
  5. 5.
    Henderson GL, Harkey MR, Gershwin ME et al (1999) Effects of ginseng components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 65:209–214CrossRefGoogle Scholar
  6. 6.
    He N, Edeki T (2004) The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes. Am J Ther 11:206–212PubMedCrossRefGoogle Scholar
  7. 7.
    Liu Y, Zhang JW, Li W et al (2006) Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. J Toxicol Sci 91:356–364CrossRefGoogle Scholar
  8. 8.
    Hao M, Zhao Y, Chen P et al (2008) Structure–activity relationship and substrate-dependent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymes. PloS One 3:e2697PubMedCrossRefGoogle Scholar
  9. 9.
    Etheridge AS, Black SR, Patel PR et al (2007) An in vitro evaluation of cytochrome P450 inhibition and p-glycoprotein interaction with goldenseal, ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med 73:731–741PubMedCrossRefGoogle Scholar
  10. 10.
    Aithal GP, Day CP, Kesteven PJL et al (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353:717–719PubMedCrossRefGoogle Scholar
  11. 11.
    Kirchheiner J, Brockmoller J (2005) Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 77:1–16PubMedCrossRefGoogle Scholar
  12. 12.
    Tam TW, Liu R, Arnason JT et al (2009) Actions of ethnobotanically selected Cree anti-diabetic plants on human cytochrome P450 isoforms and flavin-containing monooxygenase 3. J Ethnopharmacol 126:119–126PubMedCrossRefGoogle Scholar
  13. 13.
    Yu R, Brown PN (2008) Single laboratory validation study for the determination of ginsenoside content in Panax ginseng C.A. Meyer and P. quinquefolius L. Raw Materials and finished Products by High Pressure Liquid Chromatography. 5th Annual NHP Research Conference Toronto Ontario, March 27–29, 2008Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Alice Luu
    • 1
  • Brian C. Foster
    • 2
    • 3
  • Kristina L. McIntyre
    • 4
  • Teresa W. Tam
    • 2
  • John T. Arnason
    • 4
  1. 1.Department of BiologyMcMaster UniversityHamiltonCanada
  2. 2.Department of Cellular and Molecular MedicineUniversity of OttawaOttawaCanada
  3. 3.Therapeutic Products Directorate, Health CanadaOttawaCanada
  4. 4.Department of BiologyUniversity of OttawaOttawaCanada

Personalised recommendations